Citalopram

In a randomized controlled trial of 650 adults with moderate-to-severe major depression, citalopram at doses of 40 and 60 mg/day showed significantly greater improvement than placebo on all efficacy measures, with particularly robust effects on depressed mood and melancholia symptoms. The medication was well tolerated with only 15% discontinuation for adverse events.

Comprehensive review confirming citalopram's mechanism as an SSRI with minimal effects on norepinephrine and dopamine reuptake, and low affinity for other receptor systems. Toxicity is not common even at doses up to 100 mg, though serotonin hyperactivity is possible.

Systematic review of 74 studies examining citalopram's clinical efficacy and tolerability in depressive and anxiety disorders, with analysis of pharmacokinetics, safety, adverse reactions, and drug interactions across vulnerable populations including children, elderly, and those with metabolic diseases.

In a randomized controlled trial of 650 adults with moderate-to-severe major depression, citalopram at doses of 40 and 60 mg/day showed significantly greater improvement than placebo on all efficacy measures, with particularly robust effects on depressed mood and melancholia symptoms. The medication was well tolerated with only 15% discontinuation for adverse events.

Systematic review of 74 studies examining citalopram's clinical efficacy and tolerability in depressive and anxiety disorders, with analysis of pharmacokinetics, safety, adverse reactions, and drug interactions across vulnerable populations including children, elderly, and those with metabolic diseases.

In a randomized controlled trial of 650 adults with moderate-to-severe major depression, citalopram at doses of 40 and 60 mg/day showed significantly greater improvement than placebo on all efficacy measures, with particularly robust effects on depressed mood and melancholia symptoms. The medication was well tolerated with only 15% discontinuation for adverse events.

In a randomized controlled trial of 650 adults with moderate-to-severe major depression, citalopram at doses of 40 and 60 mg/day showed significantly greater improvement than placebo on all efficacy measures, with particularly robust effects on depressed mood and melancholia symptoms. The medication was well tolerated with only 15% discontinuation for adverse events.

In a randomized controlled trial of 650 adults with moderate-to-severe major depression, citalopram at doses of 40 and 60 mg/day showed significantly greater improvement than placebo on all efficacy measures, with particularly robust effects on depressed mood and melancholia symptoms. The medication was well tolerated with only 15% discontinuation for adverse events.

In a randomized controlled trial of 650 adults with moderate-to-severe major depression, citalopram at doses of 40 and 60 mg/day showed significantly greater improvement than placebo on all efficacy measures, with particularly robust effects on depressed mood and melancholia symptoms. The medication was well tolerated with only 15% discontinuation for adverse events.

In a randomized controlled trial of 650 adults with moderate-to-severe major depression, citalopram at doses of 40 and 60 mg/day showed significantly greater improvement than placebo on all efficacy measures, with particularly robust effects on depressed mood and melancholia symptoms. The medication was well tolerated with only 15% discontinuation for adverse events.